These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32597514)

  • 1. Efficacy and safety of high-dose intravenous iron as the first-choice therapy in outpatients with severe iron deficiency anemia.
    Jericó C; Beverina I; Quintana-Diaz M; Salvadori U; Melli C; Rondinelli MB; Recasens V; Brando B; Garcia-Erce JA
    Transfusion; 2020 Jul; 60(7):1443-1449. PubMed ID: 32597514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S; Maltez C; Lopes AI
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
    Tabish M; Agarwal S; Gopi S; Rana R; Ahmed S; Gunjan D; Sharma S; Saraya A
    Am J Gastroenterol; 2024 Oct; 119(10):2061-2069. PubMed ID: 38517084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
    J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department.
    Motta I; Mantovan G; Consonni D; Brambilla AM; Materia M; Porzio M; Migone De Amicis M; Montano N; Cappellini MD
    Intern Emerg Med; 2020 Jun; 15(4):629-634. PubMed ID: 31707563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
    Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
    Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
    Steinmetz T; Tschechne B; Harlin O; Klement B; Franzem M; Wamhoff J; Tesch H; Rohrberg R; Marschner N
    Ann Oncol; 2013 Feb; 24(2):475-482. PubMed ID: 23071262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study.
    Coussirou J; Debourdeau A; Stancu A; Jean C; Azouza W; Chanet B; De Crozals F; Boustany R; Debourdeau P
    Support Care Cancer; 2018 Nov; 26(11):3827-3834. PubMed ID: 29797080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
    Lichtenstein GR; Onken JE
    Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.
    Salvadori U; Vittadello F; Al-Khaffaf A; Maier A; Cappelletto PC; Daves M; Raffeiner B
    Blood Transfus; 2020 May; 18(3):176-181. PubMed ID: 31855154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
    Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y
    Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.